Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
McKinsey
US Department of Justice
Queensland Health
Cantor Fitzgerald
McKesson
Moodys
Fuji
Express Scripts
UBS

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,170,717

« Back to Dashboard

Which drugs does patent 6,170,717 protect, and when does it expire?

Patent 6,170,717 protects ADVAIR HFA, FLOVENT HFA, and VENTOLIN HFA, and is included in three NDAs.

Protection for ADVAIR HFA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-five patent family members in thirty-three countries.
Summary for Patent: 6,170,717
Title: Valve for aerosol container
Abstract:Valve for an aerosol container for dispensing a suspension of a substance in a liquid propellant contained therein. The valve comprises a valve body (1) having at least one orifice (16) to allow a quantity of the suspension to pass from the container into the valve. The valve further comprises a ring (18) disposed around the valve body (1), the ring being positioned below the at least one orifice to reduce the volume of suspension that can be accommodated within the container below the at least one orifice when the container is orientated with the valve at the bottom, the ring having at least one portion of reduced axial thickness to provide a trough (19) around the valve body below the at least one orifice.
Inventor(s): Di Giovanni; Patrick (Le Vaudrueil, FR), Rogerson; Cheryl Vanessa (Essex, GB)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/331,801
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 6,170,717

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-001 Jun 8, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-002 Jun 8, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp Ltd ADVAIR HFA fluticasone propionate; salmeterol xinafoate AEROSOL, METERED;INHALATION 021254-003 Jun 8, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-003 May 14, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-002 May 14, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-001 May 14, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline VENTOLIN HFA albuterol sulfate AEROSOL, METERED;INHALATION 020983-001 Apr 19, 2001 BX RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,170,717

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9626960Dec 27, 1996
PCT Information
PCT FiledDecember 23, 1997PCT Application Number:PCT/EP97/07224
PCT Publication Date:July 09, 1998PCT Publication Number: WO98/29321

Non-Orange Book US Patents Family Members for Patent 6,170,717

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,315,173 Valve for aerosol container ➤ Subscribe
6,510,969 Valve for aerosol container ➤ Subscribe
7,350,676 Valve for aerosol container ➤ Subscribe
6,966,467 Valve for aerosol container ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,170,717

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 9901470 ➤ Subscribe
Portugal 1415934 ➤ Subscribe
Portugal 1145987 ➤ Subscribe
Portugal 958201 ➤ Subscribe
Poland 189244 ➤ Subscribe
Poland 334354 ➤ Subscribe
Peru 6399 ➤ Subscribe
New Zealand 336334 ➤ Subscribe
Norway 316771 ➤ Subscribe
Norway 993173 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Novartis
Cipla
Teva
Moodys
Queensland Health
Boehringer Ingelheim
Fish and Richardson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot